2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-121681
    K 308 36774-74-0 98%
    K 308 is a non-steroid antiinflammatory agent.
    K 308
  • HY-121711
    5-OH-HxMF 1176-88-1 98%
    5-OH-HxMF is a hydroxylated polymethoxyflavone that has anti-inflammatory, anticancer, neurotrophic and neuroprotective activities.
    5-OH-HxMF
  • HY-121743
    Ro26-4550 193744-04-6 98%
    Ro26-4550 is a low micromolar antagonist of IL-2/IL-2Rα binding with an IC50 value of 3 μM.
    Ro26-4550
  • HY-121856
    Flumizole 36740-73-5 98%
    Flumizole, a derivative of substituted 5,6-diaryl-2,3-dihydroimidazo[2,1-b]thiazoles, was synthesized and evaluated for its immunoregulatory and anti-inflammatory properties in animal models such as rat adjuvant-induced arthritis and mouse oxazolone-induced contact sensitivity assays. This compound class combines structural elements from flumizole and levamisole, aiming to enhance therapeutic efficacy. Symmetrically substituted 5,6-diaryl compounds with specific alkyl heteroatom or halogen substitutions showed optimal potency in the arthritis model. However, variations in activity were less consistent in the contact sensitivity assay. Flumizole and related compounds demonstrate potential as dual-action agents, targeting inflammation and immune modulation, offering promise for therapeutic development in immune-related disorders.
    Flumizole
  • HY-121917
    Ro 31-7837 120280-33-3 98%
    APTO-253 (LOR-253) hydrochloride is a small molecule that inhibits c-Myc expression, stabilizes G-quadruplex DNA, and induces cell cycle arrest and apoptosis in acute myeloid leukemia cells. APTO-253 hydrochloride mediates anticancer activity via induction of Kruppel-like factor 4 (KLF4) tumor suppressor. APTO-253 hydrochloride exhibits antiarthritic activity.
    Ro 31-7837
  • HY-121927
    Mobiletrex 238074-89-0 98%
    Mobiletrex is an anti folate and dihydrofolate reductase inhibitor that can be used in research on rheumatoid arthritis.
    Mobiletrex
  • HY-121975
    N-Cyclohexanecarbonylpentadecylamine 702638-84-4 98%
    N-Cyclohexanecarbonylpentadecylamine (Compound 1) is an inhibitor of N-Acylethanolamine hydrolyzing acid amidase (NAAA) with an IC50 of 4.5 μM. N-Cyclohexanecarbonylpentadecylamine can be used in the research of inflammation and pain.
    N-Cyclohexanecarbonylpentadecylamine
  • HY-121987
    15(S)-HEDE 92693-04-4 98%
    15(S)-HEDE (Compound 8) is an analogue of 15-HEDE (HY-121987A) that inhibits 5-lipoxygenase with an IC50 value of 26 μM. 15(S)-HEDE is promising for research of inflammatory disease.
    15(S)-HEDE
  • HY-121996
    Prostaglandin E2 Ethanolamide 194935-38-1 98%
    Prostaglandin E2 Ethanolamide (PGE2-EA), an analog of PGE2, can be formed enzymatically following COX-2 oxygenation of endocannabinoids. Prostaglandin E2 Ethanolamide (PGE2-EA) could modulate the production of the proinflammatory cytokine TNF-α in human blood and human monocytic cells.
    Prostaglandin E2 Ethanolamide
  • HY-122005
    AVE-9488 291756-32-6 98%
    AVE-9488 is an eNOS enhancer with the activity of protecting the heart from ischemia-reperfusion injury. AVE-9488 can upregulate eNOS expression, increase NO production, reduce myocardial ischemia-reperfusion injury, and reduce the level of reactive oxygen species.
    AVE-9488
  • HY-122049
    ENMD-1068 hydrobromide 644961-61-5 98%
    ENMD-1068 hydrobromide is a potent PAR2 antagonist. ENMD-1068 hydrobromide attenuates joint inflammation in a dose-dependent manner. ENMD-1068 hydrobromide can be used in research of joint inflammation.
    ENMD-1068 hydrobromide
  • HY-122082
    Methopterin 2410-93-7 98%
    Methopterin inhibits osteoclasts proliferation. Methopterin inhibits the activation and bone resorption function of osteoclasts, and induced osteoclasts apoptosis.
    Methopterin
  • HY-122154
    FR234938 256461-79-7 98%
    FR234938 is a non-nucleoside adenosine deaminase inhibitor with an IC50 of 17 nM for recombinant human adenosine deaminase enzyme. FR234938 has anti-rheumatic and anti-inflammatory effects.
    FR234938
  • HY-122167
    L-869298 362718-73-8 98%
    L-869298 is a potent and selective PDE4 inhibitor with an IC50 of 0.5 nM for PDE4A. L-869298 shows less active against hERG potassium channel.
    L-869298
  • HY-122179
    NUCC-555 1060469-90-0 98%
    NUCC-555 is an activin antagonist. NUCC-555 interacts with Trp25, Trp28, Phe55, Tyr93, Lys103, and Asn107 in the Activin A binding pocket. NUCC-555 blocks Activin A-mediated hepatic stellate cells (HSCs) activation. NUCC-555 promotes liver regeneration and halts fibrosis progression in chronic liver disease models. NUCC-555 inhibits Activin A-mediated ovarian cell proliferation. NUCC-555 decreases FSH levels in ovariectomized mice.
    NUCC-555
  • HY-122192
    ICAM-1988 444169-80-6 98%
    ICAM-1988 is a small molecule lymphocyte function-associated antigen-1 (LFA-1) antagonist that disrupts the LFA-1/ICAM-1 interaction and has anti-inflammatory activity.
    ICAM-1988
  • HY-122292
    Celastramycin A 188988-62-7 98%
    Celastramycin A is an antibiotic isolated from Streptomyces MaB-QuH-8, which exhibits antimicrobial activity against series of gram-negative bacteria and mycobacteria, with MICs between 0.05-3.1 μg/ml. Celastramycin A exhibits immunosuppressing efficacy in ex vivo Drosophila through immune deficiency pathway (IC50 of 0.008 μg/ml), inhibits the immunoresponse in human innate immunity through TNF-α signaling, inhibits IL-8 production in HUEVCs with IC50 of 0.06 μg/ml.
    Celastramycin A
  • HY-122295
    Dehydroleucodine 36150-07-9 99.90%
    Dehydroleucodine is a sesquiterpene lactone isolated from Artemisia douglasiana. Dehydroleucodine is a mast cell stabilizer that inhibits tmast cell degranulation induced by compound 48/80. Dehydroleucodine inudces cells apoptosis, and has gastric ulcer inhibition and antileukemic effects.
    Dehydroleucodine
  • HY-122384
    Alcindoromycin 72586-21-1 98%
    Alcindoromycin is an anthracycline antitumor antibiotic.
    Alcindoromycin
  • HY-12238G
    IWR-1 (GMP) 1127442-82-3 98%
    IWR-1 (IWR-1-endo) (GMP) is the IWR-1 (HY-12238) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. IWR-1 (IWR-1-endo) is a tankyrase inhibitor targeting Wnt/β-catenin (IC50 = 180 nM). IWR-1 compromises critical steps of the canonical Wnt signaling, namely translocation of β-catenin to the nucleus and subsequent TCF/LEF activation and expression of Wnt/β-catenin downstream targets. IWR-1 promotes β-catenin phosphorylation by promoting stability of Axin-scaffolded destruction complexes. IWR-1 can be studied in research for anti-tumor purposes, and diseases such as osteosarcoma, colorectal cancer and psoriasis.
    IWR-1 (GMP)
Cat. No. Product Name / Synonyms Application Reactivity